Prof Gunter Von Minckwitz talks to ecancer about assessing neoadjuvant therapy in breast cancer and recent developments at IMPAKT 2012 in Brussels, May 2012.

Recent developments have allowed patients to benefit by receiving better treatment through more accurate prognostics on the subtype of their tumour. There are now a series of trials that show an increase of complete pathological response in patients with HER2+ tumours.

Filming Supported by Amgen